Study on Abemaciclib for Patients with Recurrent Brain Tumors

Inclusion Criteria

• For Cohort A: Patients with specific types of brain tumors (IDHwt, RB intact, grade II or III glioma) that have returned after initial treatment, including surgery and radiation. No limit on previous treatments.
• For Cohort B: Patients with any grade of glioma who are scheduled for surgery and whose participation won't delay their surgery.
• For Cohort C: Patients with certain types of brain tumors (IDH mutant glioma, meningioma, schwannoma, PCNSL, ependymoma) that have returned after standard treatment. Special cases may be considered for inclusion.
• All patients must be 18 years or older, able to swallow pills, and in good enough health to participate (KPS score of 60 or higher).
• Must have specific blood test results and be stable on any steroid medication for more than 5 days before the study starts.
• Must have recovered from previous treatments and be able to undergo MRI or CT scans.
• Women of childbearing potential must have a negative pregnancy test and agree to use contraception during and after the study. Men must also agree to use birth control.
• Must provide informed consent and be willing to follow the study schedule.

Exclusion Criteria

• No limit on previous treatments.
• Cannot have significant bleeding in the brain.
• Cannot be on other cancer treatments.
• Cannot have allergies to similar drugs or serious medical conditions that would interfere with the study.
• Cannot have a history of certain heart conditions or be HIV-positive on antiretroviral therapy.
• Cannot have active fungal or viral infections.
• Cannot be on certain medications or be pregnant or breastfeeding.
• Must avoid grapefruit juice.
• Cannot have another active cancer or be in another treatment trial, except for supportive care or quality of life studies.